| Market Capitalization (Millions $) |
11 |
| Shares
Outstanding (Millions) |
11 |
| Employees |
20 |
| Revenues (TTM) (Millions $) |
- |
| Net Income (TTM) (Millions $) |
-11 |
| Cash Flow (TTM) (Millions $) |
-1 |
| Capital Exp. (TTM) (Millions $) |
0 |
Business Description
Brainstorm Cell Therapeutics Inc. is a biotechnology company that specializes in the development and commercialization of stem cell-based therapies for neurodegenerative diseases. The company is focused on developing its proprietary NurOwn technology platform, which is designed to induce autologous (the patient's own) mesenchymal stem cells to secrete neurotrophic factors that can promote the survival and growth of neurons.
Brainstorm's lead product candidate is NurOwn, which is currently being evaluated in clinical trials for the treatment of Amyotrophic Lateral Sclerosis (ALS), also known as Lou Gehrig's disease. The company has also initiated early-stage research programs for other neurodegenerative disorders, including Parkinson's disease and Multiple Sclerosis.
The therapies developed by Brainstorm Cell Therapeutics hold the potential to address the significant unmet medical need in neurodegenerative diseases, where current treatment options are limited and mostly focus on managing symptoms rather than providing a cure. The company is committed to advancing its research and development efforts to bring much-needed treatments to patients suffering from these debilitating conditions.
Company Address: 1325 Avenue of Americas, 28th Floor New York 10019 NY
Company Phone Number: 488-0460 Stock Exchange / Ticker: BCLI
|
